All In Biotech

NDA 213006 · Sumitomo Pharma Am

Gemtesa

Vibegron · Oral · beta3-Adrenergic Agonist

Novel

Last checked: Nov 20, 2026Latest source record: Dec 18, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2020

Dec 23, 2020

Approved uses

2

Original approval plus efficacy supplements

Registered trials

15

8 Phase 3, 2 recruiting

FAERS reports

8,828

2,702 serious, 462 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 1, 2025.

GEMTESA is a beta-3 adrenergic agonist indicated for the treatment of: overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults. ( 1.1 ) overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adult males on pharmacological therapy for benign prostatic hyperplasia (BPH). ( 1.2 ) 1.1 Overactive Bladder in Adults GEMTESA ® is indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults. 1.2 Overactive Bladder in Adult Males with Benign Prostatic Hyperplasia (BPH) GEMTESA is indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adult males on pharmacological therapy for benign prostatic hyperplasia (BPH).

Mechanism: Vibegron is a selective human beta-3 adrenergic receptor agonist. Activation of the beta-3 adrenergic receptor increases bladder capacity by relaxing the detrusor smooth muscle during bladder filling.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • GEMTESA · VIBEGRON 75MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Vibegron" as an intervention, any sponsor and status, largest first.

All 15 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective1,194
  • diarrhoea440
  • headache419
  • urinary tract infection392
  • urinary retention335
  • death332
  • fatigue308
  • nausea288
  • drug effect less than expected285
  • inability to afford medication266
  • constipation263
  • dizziness243

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20162
20173
20186
20198
202019
2021211
2022191
20231,842
20242,002
20252,278
20262,266

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Gemtesa (Vibegron)

2024 spending

$945M

Beneficiaries

320,270

1,361,795 claims

Per beneficiary

$2,951

$15.88 per unit

View as table
YearSpending
2020$0
2021$28,352,679
2022$164,478,183
2023$508,474,527
2024$945,088,935

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 43 on PubMed

Sponsor: Sumitomo Pharma Am

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.